Cardiovascular disease (CVD) is one of the most common diseases worldwide. The underlying pathogenesis of the disease has not yet been determined, but many factors have been identified. Tet methylcytosine dioxygenase 2 (TET2) is one of the epigenetic factors involved in regulating many genes. Therefore, based on the studies shown, this factor plays an important role in preventing the occurrence of CVD. TET2 has been shown to increase angiogenesis by expressing Robo4. It also increases the activity of Matrix metalloproteinases (MMPs) and stimulates the secretion of Vascular endothelial growth factor angiogenesis. On the other hand, it has been shown that TET2 regulates the expression of several genes and the development of the heart during the embryonic period due to its oxygenating role. TET2 has been shown to regulates the expression of the genes such as Ying Yang1 (YY1), Sox9b, Inhbaa and many other genes that ultimately lead to the differentiation of cardiomyocytes. On the other hand, it has been shown that some Long non coding RNA and MicroRNAs reduce TET2 expression and CVD. Finally, it is concluded that inducing TET2 expression can be a good therapeutic strategy to prevent or improve CVD.

心血管疾病（CVD）是全球最常见的疾病之一。该疾病的潜在发病机制尚未确定，但已确定了许多因素。Tet 甲基胞嘧啶双加氧酶 2 (TET2) 是参与调节许多基因的表观遗传因子之一。因此，根据研究表明，该因素在预防心血管疾病的发生中起着重要作用。TET2 已被证明通过表达 Robo4 来增加血管生成。它还增加基质金属蛋白酶 (MMP) 的活性并刺激血管内皮生长因子血管生成的分泌。另一方面，已经表明 TET2 由于其充氧作用而在胚胎期调节多种基因的表达和心脏的发育。TET2 已被证明可以调节 Ying Yang1 (YY1)、Sox9b、Inhbaa 和许多其他最终导致心肌细胞分化的基因的表达。另一方面，已经表明一些长链非编码 RNA 和 MicroRNA 会降低 TET2 表达和 CVD。最后，得出结论，诱导 TET2 表达可以是预防或改善 CVD 的良好治疗策略。